CROs in Asian Giants India and China Create Alliance To Conduct Clinical Trials To Keep Pace With Exploding Demand
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In response to rapidly accelerating demand for clinical drug research across Asia, India's GVK Biosciences and China's Excel PharmaStudies are crafting an alliance to jointly conduct trials in both countries
You may also be interested in...
India's Largest CRO Siro Clinpharm Is Up For Grabs; Will Biocon Bag It Or Is A Bidding War On?
MUMBAI - The extensively polarized Indian clinical research industry is finally set for a top-level consolidation as India's biotechnology company Biocon is reported to have made a bid to buy out Siro Clinpharm - one of the earliest entrants and an established player in the clinical and data management business
India's Largest CRO Siro Clinpharm Is Up For Grabs; Will Biocon Bag It Or Is A Bidding War On?
MUMBAI - The extensively polarized Indian clinical research industry is finally set for a top-level consolidation as India's biotechnology company Biocon is reported to have made a bid to buy out Siro Clinpharm - one of the earliest entrants and an established player in the clinical and data management business
Citing Lack Of Infrastructure, Brakes Are Put On Allowing Phase I Trials In India
MUMBAI - After building great expectations on allowing Phase I human studies in India, the government has now back tracked from taking any concrete decisions until the "right infrastructure" is put in place